EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Inhalation Sciences Sweden AB (ISAB) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Inhalation Sciences Sweden AB SEK 0.10, price SEK 0.08, upside +26.4%, quality 36 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · SE

IS Thin data Oct 4, 2026

Inhalation Sciences Sweden AB

ISAB · ST

SpeculativeUpside exists, but weak quality makes the signal speculative.

Fair value kr 0.1029 · Undervalued (+26.4%)
Low debt
Mixed vs. peers (5/10)
Quality 36/100
Weak Growth (revenue 3y −37.1 %/yr in SEK)
Loss-making · -103.1% net margin (TTM)
Negative free cash flow
Narrow moat 4/100
Thin data
⚠ Dilution
Watch Inhalation Sciences Sweden AB for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 11.95 kr 0.0810 Fair Value kr 0.1029 May 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 4, 2026.

How to read this chart

60‑month range kr 0.0810 – kr 11.95 · fair‑value band kr 0.0683 – kr 0.1237 · the kr 0.0814 price screens below the kr 0.1029 fair value. Dashed = 300-day average. As of Oct 4, 2026.

Follow Inhalation Sciences Sweden in your weekly email

Every Wednesday you see whether Inhalation Sciences Sweden is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Inhalation Sciences Sweden AB (publ) develops and sells labtech equipment for inhalation research in Sweden.

Show more

Inhalation Sciences Sweden AB (publ) develops and sells labtech equipment for inhalation research in Sweden. The company offers PreciseInhale, a laboratory system that allows scientists to measure how inhaled particles act in lungs and affect the health; DissolvIt, which enables in vitro simulation of dissolution and absorption of respirable particles in the lung epithelium; XposeALI, a 3D cell exposure module that combines aerosol capability with 3D cell models cultured at an air liquid interface; Nose-only inhalation, a standard method of exposure used in preclinical testing of inhalation drugs, as well as for inhalation toxicity studies in rodents; and intratracheal exposure module, an unique technology delivering aerosol directly to the lungs, bypassing the nose, and to spontaneously breathing rodents. Inhalation Sciences Sweden AB (publ) was incorporated in 2004 and is based in Huddinge, Sweden.

Stock analysis

Inhalation Sciences Sweden AB (ISAB) currently trades at kr 0.0814, while our model-based Fair Value estimate is kr 0.1029, implying the stock looks roughly 20.9% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 92/100, which puts the evidence level at low.

Scenario range: kr 0.0683 (bear) to kr 0.1237 (bull), the price of kr 0.0814 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Inhalation Sciences Sweden AB reported revenue of 3.0M SEK in FY2025 versus 12.2M SEK in FY2022, a compound −37.1%/yr. Reported net income was −10.2M SEK in FY2025.

Key figures

Market cap 4.2M SEK (≈ $415K) · P/S ratio 0.50 · EPS (TTM) kr −0.1700 · Net margin −103% · Return on equity −90.0% · Return on assets (EBIT) −67.0% · Operating margin −65.0% · Revenue (TTM) 8.3M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 24 out of 100 (low confidence).

What moves the price

The share trades about 84% below its 52-week high and at its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 26%, ISAB screens cheaper than that median.

Fair Value models

Bear kr 0.0683 Fair Value kr 0.1029 Bull kr 0.1237
Price kr 0.0814 · Upside +26.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) kr 0.0700 kr 0.1000 kr 0.1400 54
All 1 models by family
Asset-Based
NCAV (Graham) kr 0.0700 kr 0.1000 kr 0.1400 54

Open the full fair value analysis →

Notify me when ISAB reaches fair value

Put ISAB on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 36/100

Of which business quality 36 · Market factors (momentum, volatility) 16

Profitability 13
Margins and returns on capital today
Quality Growth 0
Are margins and returns improving?
Cashflow 34
Earnings quality: real cash, not paper profit
Fin. Strength 75
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 2
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−72.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−37.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−98.6% (2022) → −333.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch ISAB, get fair value alerts →

Compare Inhalation Sciences Sweden AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 336 stocks

Beats the industry median on 4/8 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 36 · Bottom 25%
Fair Value upside +26.4% · Top 25%
Profitability
Return on assets −47.3% · Bottom 25%
Net margin (TTM) −103.1% · Bottom 25%
Operating margin (TTM) −65.0% · Bottom 25%
Growth and dividend
Revenue growth 246.8% · Top 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.06× · Cheapest 25%
P/S (TTM) 0.05× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)69 · sector 6
FUTURE (revenue growth)100 · sector 31
PAST (return on equity)0 · sector 16
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)0 · sector 39

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $98.83 $74.79 −24%
Medtronic plc MDT $87.09 $65.61 −25%
Stryker Corporation SYK $278.77 $306.65 +10%
Boston Scientific Corporation BSX $43.65 $48.02 +10%
Edwards Lifesciences Corporation EW $85.19 $81.94 −4%
Siemens Healthineers AG SHL €37.86 €35.19 −7%
DexCom, Inc DXCM $85.36 $93.90 +10%
GE HealthCare Technologies Inc GEHC $66.63 $70.37 +6%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥153.86 ¥169.25 +10%
Koninklijke Philips N.V PHIA €21.87 €15.23 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Inhalation Sciences Sweden AB · Fair Value
kr 0.1029 +21%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Inhalation Sciences Sweden AB Fair Value". https://www.fairvalue-calculator.com/stock/ISAB

Frequently asked questions

Is Inhalation Sciences Sweden AB (ISAB) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of kr 0.1029 versus a price of kr 0.0814, about +26% upside (undervalued).
What is the fair value of ISAB?
Our model-based fair value for Inhalation Sciences Sweden AB is kr 0.1029 (as of Oct 4, 2026), built from audited fundamentals. The current price: kr 0.0814.
What is the quality score of ISAB?
Inhalation Sciences Sweden AB has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Inhalation Sciences Sweden AB (ISAB)?
Our model-based price target is the fair value of kr 0.1029 (as of Oct 4, 2026) from 1 valuation models. Cautious scenario kr 0.0683, optimistic scenario kr 0.1237. It is a calculation from audited fundamentals, not an analyst target.
What is the Inhalation Sciences Sweden AB stock forecast for 2026?
Our models put fair value at kr 0.1029, about +26% upside versus a price of kr 0.0814 (undervalued). Cautious scenario kr 0.0683, optimistic scenario kr 0.1237. The calculation is refreshed regularly with new filings.
What is the revenue of Inhalation Sciences Sweden AB (ISAB)?
Inhalation Sciences Sweden AB reported trailing-twelve-month revenue of about 8.3M SEK (latest available figure, as of Oct 4, 2026).
What is the intrinsic value of Inhalation Sciences Sweden AB (ISAB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Inhalation Sciences Sweden AB it is kr 0.1029 per share (as of Oct 4, 2026), against a price of kr 0.0814. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Inhalation Sciences Sweden AB stock overvalued or undervalued in 2026?
As of Oct 4, 2026, ISAB trades below its calculated fair value: price kr 0.0814, fair value kr 0.1029, a gap of about +26% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ISAB?
No. The price is what the market pays today (kr 0.0814); the fair value is what the company's own numbers justify (kr 0.1029). For Inhalation Sciences Sweden AB the two are kr 0.0215 per share apart. That gap is exactly why we show both numbers side by side.
How much is Inhalation Sciences Sweden AB worth?
The market values Inhalation Sciences Sweden AB at about 4.2M SEK (market capitalisation, as of Oct 4, 2026). Per share that is kr 0.0814; our models calculate a fair value of kr 0.1029 per share.
What do the bullish and bearish scenarios say about ISAB?
Our models span a range for Inhalation Sciences Sweden AB: cautious scenario kr 0.0683, base kr 0.1029, optimistic kr 0.1237 per share (as of Oct 4, 2026, price kr 0.0814). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Inhalation Sciences Sweden AB (ISAB)?
Balance-sheet figures for Inhalation Sciences Sweden AB (as of Oct 4, 2026): return on equity −90.0%. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is ISAB from its 52-week high?
Inhalation Sciences Sweden AB trades at kr 0.0814, about 84% below its 52-week high of kr 0.5200 and at the low of kr 0.0810 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.1029 is for.
Which stocks are comparable to Inhalation Sciences Sweden AB?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Inhalation Sciences Sweden AB stock attractive at the current price?
The data as of Oct 4, 2026: price kr 0.0814, calculated fair value kr 0.1029 (+26%), Quality Score 36/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ISAB calculated?
We run Inhalation Sciences Sweden AB through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.1029, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. Inhalation Sciences Sweden AB currently trades 21 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Inhalation Sciences Sweden AB (ISAB)?
The closing price on Oct 2, 2026 was kr 0.0814. Our model-based fair value is kr 0.1029, about +26% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Inhalation Sciences Sweden AB right now?
A fairly wide model range (kr 0.0683 to kr 0.1237) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Inhalation Sciences Sweden AB

How large is the market capitalisation of Inhalation Sciences Sweden AB (ISAB)?
The market capitalisation of Inhalation Sciences Sweden AB is 4.2M SEK (≈ $415K). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Inhalation Sciences Sweden AB (ISAB)?
The price-to-sales ratio of Inhalation Sciences Sweden AB is 0.50 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Inhalation Sciences Sweden AB (ISAB)?
Earnings per share at Inhalation Sciences Sweden AB are kr −0.1700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Inhalation Sciences Sweden AB (ISAB)?
The net margin of Inhalation Sciences Sweden AB is −103% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Inhalation Sciences Sweden AB (ISAB)?
The return on equity (ROE) of Inhalation Sciences Sweden AB is −90.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Inhalation Sciences Sweden AB (ISAB)?
On an EBIT basis the return on assets of Inhalation Sciences Sweden AB is −67.0% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Inhalation Sciences Sweden AB (ISAB)?
The operating margin of Inhalation Sciences Sweden AB is −65.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Inhalation Sciences Sweden AB (ISAB)?
Revenue at Inhalation Sciences Sweden AB is growing +247% versus a year earlier (3y avg −37.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Inhalation Sciences Sweden AB (ISAB) generate?
The free cash flow of Inhalation Sciences Sweden AB is −10.8M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Inhalation Sciences Sweden AB in the live analysis

One click puts Inhalation Sciences Sweden AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.